This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell
Vistagen’s Fasedienol did not show statistically significant improvements on primary and secondary endpoints. The treatment did not show any difference between subjects receiving the drug and the placebo group for the secondary endpoints. However, the study showed that data from safety, tolerability, and post-hoc analysis were positive. The company now plans to discuss with the … Read more